## Core Concept
The question assesses knowledge of prognostic markers in breast cancer, focusing on molecular and genetic factors that influence patient outcomes. Breast cancer prognosis is significantly impacted by the presence or absence of specific receptors and genetic mutations.

## Why the Correct Answer is Right
Markers associated with a good prognosis in breast cancer include estrogen receptor-positive (ER+), progesterone receptor-positive (PR+), and HER2-negative status. ER and PR positivity indicate that the cancer is likely to respond to hormonal therapy, which generally confers a better prognosis. On the other hand, HER2 positivity (HER2+) is often associated with a more aggressive disease but also indicates potential responsiveness to targeted therapies like trastuzumab.

## Why Each Wrong Option is Incorrect
- **Option C:** HER-2/neu (receptors) +ve is generally associated with a worse prognosis due to its link with more aggressive tumor behavior. However, with the advent of targeted therapies, HER2+ status also offers a therapeutic avenue.
- **Option E:** p53 gene +ve (mutation) is typically associated with a poorer prognosis. The p53 gene is a tumor suppressor gene, and mutations in this gene can lead to uncontrolled cell growth and resistance to apoptosis.
- **Option D:** CD44 receptor +ve is associated with cancer stem cells and has been linked to metastasis and poor prognosis in various cancers, including breast cancer.

## Clinical Pearl / High-Yield Fact
A key clinical pearl is that breast cancers can be classified into subtypes based on receptor status (luminal A: ER+, PR+, HER2-; luminal B: ER+, PR+, HER2+; HER2-enriched: ER-, PR-, HER2+; and triple-negative: ER-, PR-, HER2-), which guides treatment and predicts prognosis. Patients with ER+ and/or PR+ tumors generally have a better prognosis and are more likely to benefit from endocrine therapy.

## Correct Answer: B.